Fluorescent Probe for Assessment of Renal Elimination (FLARE)
研究概览
地位
详细说明
The majority of acutely ill patients exhibit changes in renal function due to inflammation, increased solute generation, and iatrogenic factors such as fluid resuscitation and vasopressors. The pharmacokinetics of renally eliminated medications (eg. levetiracetam, cefepime, vancomycin) are frequently affected by inflammatory processes despite normal estimations in creatinine clearance resulting in suboptimal serum drug concentrations and therapeutic failure. Despite the prevalence of fluctuations in renal function in acute illness, real-time assessment is limited to monitoring of serum biomarkers such as creatinine and cystatin C, as well as urine output, which typically lag behind important changes in function. Furthermore, use of creatinine clearance equations based on anthropomorphic data correlates poorly with actual renal function, potentially misleading clinicians as to the progression of disease and the need for dose adjustment of important medications in this vulnerable population.
Limitations of current approaches for evaluating renal function in the acutely ill Estimation of GFR or creatinine clearance can be accomplished by numerous equations, the majority of which have been validated in non-critically ill adults, usually with a relatively high percent of patients with chronic kidney disease. These equations are often not accurate in patients with acutely worsening renal function. Likewise, while these equations are helpful for categorizing renal function and assessing appropriate medication dosing in otherwise healthy, ambulatory patients. Under-prediction of creatinine clearance values leads clinicians to consistently under-dose critical medications such as beta-lactam antibiotics, vancomycin, or antiseizure medications such as levetiracetam.
Proactive measurement of creatinine clearance can provide a more accurate depiction of GFR but is fraught with complications. Iohexol serum concentrations correlate well with GFR, but requires intravenous administration of iohexol, which has a small risk of infusion reaction and hypersensitivity, and serial blood samples. Measured urine creatinine clearance is also feasible but inconvenient in most hospitalized patients. mClCr requires bladder catheterization for accurate urine volume, consistent storage on ice for the duration of collection (between 8 and 24 hours), and prompt delivery of the large volume container to the local laboratory for creatinine analysis. Each of these criteria introduce variability into the measurement and are often unnoticed or undocumented, introducing inaccuracy into the mClCr values. The lack of a real-time, accurate assessment of creatinine clearance in the acutely ill population is a gap in practice and represents a resolvable problem in the process of individualized and precision dosing of medications in this vulnerable and high-risk population.
This study represents an important innovation in advancing the understanding of fluctuations in renal function during acute illness. The current study will validate the safety of transdermal GFR monitoring to provide real-time measurement of renal function in patients with stable renal function. Further, the reliability of transdermal GFR monitoring will be compared to current standards of renal function assessment. The results of this study will advance the field by validating the use of a real-time physiologic assessment of GFR rather than using labor intensive, invasive tests that may lag behind current renal function. Numerous important gaps remain with this new technology, including use primarily in the ambulatory, stable renal function populations. Thus, this study is potentially the first step in evaluating renal function across the acute care continuum.
研究类型
注册 (估计的)
阶段
- 第四阶段
联系人和位置
学习联系方式
- 姓名:Aaron Cook, PharmD
- 电话号码:18592578444
- 邮箱:amcook0@uky.edu
学习地点
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- UKHealthCare/University of Kentucky
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- 18-65 years old
- critically ill or acutely ill hospitalized patients admitted to the intensive care unit
- Stable/normal renal function
Exclusion Criteria:
- Prisoners
- Pregnant women
- Laboratory evidence of unstable kidney function (KDIGO AKI stage 1-3--This includes subjects with Scr > 1.5x baseline)
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:MediBeacon Transdermal Glomerular Filtration Rate (GFR) Monitoring
|
IV push of relmapirazin (Lumitrace) prior to use of the tGFR device
Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.
The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.
8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR & other renal function measures.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Transdermal Glomerular Filtration Rate (tGFR) Monitoring Accuracy
大体时间:8 Hours
|
Accuracy of transdermal glomerular filtration rate (GFR) monitoring compared with measured urine creatinine clearance.
|
8 Hours
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Relmapirazin Elimination Half-Life
大体时间:12 hours
|
Elimination half-life of Relmapirazin calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
|
Iohexol Elimination Half-Life
大体时间:12 hours
|
Elimination half-life of Iohexol calculated from serial serum concentration measurements obtained over 12 hours following intravenous administration.
|
12 hours
|
合作者和调查者
赞助
调查人员
- 首席研究员:Aaron M Cook, PharmD、University of Kentucky College of Pharmacy, Department of Pharmacy Practice & Science
- 研究主任:Juan-Carlos Aycinena, MD、University of Kentucky College of Medicine, Department of Nephrology
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.